In patients with R/R follicular #lymphoma, treatment with the triplet combo of #tafasitamab, #lenalidomide, and #rituximab led to significantly improved PFS compared with the SOC combo of lenalidomide plus rituximab, at a median 22.4 months vs. 13.9: https://ow.ly/PSaT50YBgcw
#HemeSky

Tafasitamab Therapy Significantly Reduces Disease Progression Risks in Follicular Lymphoma Patients A recent study shows that adding Tafasitamab to standard treatments for follicular lymphoma patients significantly reduces disease progression risks by 57%.

Tafasitamab Therapy Significantly Reduces Disease Progression Risks in Follicular Lymphoma Patients #USA #San_Diego #Follicular_Lymphoma #Tafasitamab #BC_Cancer